Prediction of major outcomes in patients with malignant hypertension using machine learning: A report from the West Birmingham malignant hypertension registry.

IF 4.4 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Antonios A Argyris, Hironori Ishiguchi, Yang Chen, Yalin Zheng, Alena Shantsila, Eduard Shantsila, D Gareth Beevers, Gregory Y H Lip
{"title":"Prediction of major outcomes in patients with malignant hypertension using machine learning: A report from the West Birmingham malignant hypertension registry.","authors":"Antonios A Argyris, Hironori Ishiguchi, Yang Chen, Yalin Zheng, Alena Shantsila, Eduard Shantsila, D Gareth Beevers, Gregory Y H Lip","doi":"10.1111/eci.70052","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Malignant hypertension (MHT) is a rare, yet severe condition with high morbidity and mortality. We aimed to assess the potential of machine learning (ML) algorithms in forecasting prognostic outcomes in MHT patients.</p><p><strong>Methods: </strong>Data from the West Birmingham MHT Registry were used. We evaluated the efficacy of 9 ML algorithms, CatBoost, Decision Tree (DT), Light-Gradient Boosting Machine (LightGBM), K-Nearest Neighbours (KNN), Logistic Regression (LR), Multi-Layer Perceptron (MLP), Random Forest (RF), Support Vector Machine (SVM) and XGBoost in predicting a composite outcome of all-cause mortality/dialysis. Evaluation metrics included the area under the receiver operating characteristic curve (AUC) and F1 score. SHapley Additive exPlanations values were employed to quantify the importance of each feature.</p><p><strong>Results: </strong>The cohort comprised 385 individuals with MHT (mean age 48 ± 13 years, 66% male). During a median follow-up of 11 (interquartile range: 3-18) years, 282 patients (73%) experienced the composite outcome. Among 24 demographic and clinical variables, 16 were selected into the ML models. The SVM, LR, and MLP models exhibited robust predictive performance, achieving AUCs of .81 (95% CI: .70-.90), .82 (95% CI: .71-.92) and .81 (95% CI: .71-.90), respectively. Furthermore, these models demonstrated high F1 scores (SVM: .75, LR: .80. MLP: .75). Age, smoking, follow-up systolic blood pressure, and baseline creatinine were commonly identified as primary prognostic features in both SVM and LR models.</p><p><strong>Conclusions: </strong>The application of ML algorithms facilitates effective prediction of prognostic outcomes in MHT patients, illustrating their potential utility in clinical decision-making through more targeted risk stratification and individualised patient care.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70052"},"PeriodicalIF":4.4000,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/eci.70052","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Malignant hypertension (MHT) is a rare, yet severe condition with high morbidity and mortality. We aimed to assess the potential of machine learning (ML) algorithms in forecasting prognostic outcomes in MHT patients.

Methods: Data from the West Birmingham MHT Registry were used. We evaluated the efficacy of 9 ML algorithms, CatBoost, Decision Tree (DT), Light-Gradient Boosting Machine (LightGBM), K-Nearest Neighbours (KNN), Logistic Regression (LR), Multi-Layer Perceptron (MLP), Random Forest (RF), Support Vector Machine (SVM) and XGBoost in predicting a composite outcome of all-cause mortality/dialysis. Evaluation metrics included the area under the receiver operating characteristic curve (AUC) and F1 score. SHapley Additive exPlanations values were employed to quantify the importance of each feature.

Results: The cohort comprised 385 individuals with MHT (mean age 48 ± 13 years, 66% male). During a median follow-up of 11 (interquartile range: 3-18) years, 282 patients (73%) experienced the composite outcome. Among 24 demographic and clinical variables, 16 were selected into the ML models. The SVM, LR, and MLP models exhibited robust predictive performance, achieving AUCs of .81 (95% CI: .70-.90), .82 (95% CI: .71-.92) and .81 (95% CI: .71-.90), respectively. Furthermore, these models demonstrated high F1 scores (SVM: .75, LR: .80. MLP: .75). Age, smoking, follow-up systolic blood pressure, and baseline creatinine were commonly identified as primary prognostic features in both SVM and LR models.

Conclusions: The application of ML algorithms facilitates effective prediction of prognostic outcomes in MHT patients, illustrating their potential utility in clinical decision-making through more targeted risk stratification and individualised patient care.

利用机器学习预测恶性高血压患者的主要预后:一份来自西伯明翰恶性高血压登记处的报告。
背景:恶性高血压(MHT)是一种罕见但严重的疾病,发病率和死亡率高。我们旨在评估机器学习(ML)算法在预测MHT患者预后结果方面的潜力。方法:使用来自西伯明翰MHT登记处的数据。我们评估了9种ML算法,CatBoost、决策树(DT)、光梯度增强机(LightGBM)、k近邻(KNN)、逻辑回归(LR)、多层感知器(MLP)、随机森林(RF)、支持向量机(SVM)和XGBoost在预测全因死亡率/透析综合结果方面的功效。评价指标包括受试者工作特征曲线下面积(AUC)和F1评分。SHapley加性解释值用于量化每个特征的重要性。结果:该队列包括385例MHT患者(平均年龄48±13岁,66%为男性)。在中位随访11年(四分位数间距:3-18年)期间,282例患者(73%)出现了复合结局。在24个人口学和临床变量中,16个被选择到ML模型中。SVM、LR和MLP模型表现出稳健的预测性能,auc分别为0.81 (95% CI: 0.70 - 0.90)、0.82 (95% CI: 0.71 - 0.92)和0.81 (95% CI: 0.71 - 0.90)。此外,这些模型具有较高的F1得分(SVM: 0.75, LR: 0.80)。延时:炮)。在SVM和LR模型中,年龄、吸烟、随访收缩压和基线肌酐通常被认为是主要的预后特征。结论:ML算法的应用有助于有效预测MHT患者的预后结果,通过更有针对性的风险分层和个性化患者护理,说明ML算法在临床决策中的潜在效用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.50
自引率
3.60%
发文量
192
审稿时长
1 months
期刊介绍: EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信